cergentis产品代理
cergentis产品代理
Cergentis 已成为全球生物制药行业和全球领先研究机构表征基因工程细胞系、细胞和基因治疗产品以及动物模型的首选合作伙伴。我们开发和销售用于（转）基因和基因编辑事件的靶向和完整测序的试剂盒和服务，并为这些领域的研发支持提供服务。
除了 Cergentis 当前业务的收入增长之外，该公司还开发了其核心技术的其他应用程序。最近的一项发展是 FFPE-TLC（靶向位点捕获）技术，我们可以通过该技术在一次测试中检测 FFPE 肿瘤活检样本中的所有相关突变。因此，我们努力克服 FISH 等传统技术的局限性，并使医生能够进行更小、微创的活检。
我们的使命是提高基因研究的质量：支持生物制药研发将加速新疗法的开发，为世界各地的患者带来更好的结果。
Cergentis 成立于 2012 年，是从 Hubrecht 发展生物学与干细胞研究所和荷兰皇家艺术与科学学院 (KNAW) 分拆出来的。
Cergentis is a privately held genomics company that developed the patented Targeted Locus Amplification (TLA) technology. TLA is a widely published Next Generation Sequencing (NGS) technology that offers unique advantages in the implementation of precision medicine and advanced genetic engineering.
Cergentis has established itself as the go-to partner for the characterization of genetically engineered cell lines, cell and
gene therapy products and animal models for the global biopharmaceutical industry and leading research institutes worldwide. We develop and sell kits and services for targeted and complete sequencing of (trans)genes and gene editing events and provide services for the support in R&D in these fields.
Next to growing revenue from Cergentis’ current business, the company develops additional applications of its core technology. A recent development is the FFPE-TLC (Targeted Locus Capture) technology, with which we can detect all relevant mutations in FFPE tumor biopsy samples in one single test. With this, we strive to overcome limitations of conventional techniques such as FISH as well as to enable physicians to take smaller, minimal invasive biopsies.
It is our mission to improve the quality of genetic research: supporting biopharmaceutical R&D will accelerate the development of new treatments with better outcomes for patients all over the world.
Cergentis was founded in 2012 as a spin-off from Hubrecht Institute for Development Biology & Stem Cell Research and Royal Netherlands Academy of Arts and Sciences (KNAW).
